StockData

Teva Pharmaceutical Industries vs Zoetis

TEVA and ZTS side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.

How TEVA and ZTS compare

Teva Pharmaceutical Industries is the larger company, worth 1.4 times as much as Zoetis ($49.6B against $34.5B).

On earnings, Zoetis is cheaper: it trades at 13.7× trailing earnings, against 71.0× for Teva Pharmaceutical Industries.

Zoetis grew revenue faster over the last twelve months (1.5% versus −15.2% for Teva Pharmaceutical Industries).

Zoetis keeps more of each dollar of sales as profit, with a net margin of 27.5% compared with 5.0% at Teva Pharmaceutical Industries.

Zoetis pays a dividend yielding 1.9%; Teva Pharmaceutical Industries does not pay one.

Zoetis scores higher on the StockData Score (17 against 7 for Teva Pharmaceutical Industries), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.

Key numbers

A dot marks the better figure where higher or lower is clearly better.

MetricTEVAZTS
Size and price
Market cap$49.6B$34.5B
Share price$42.57$83.48
Change, 1 year66.7%−30.9%
Change, 5 years401%−61.9%
Beta (5Y)1.150.06
Employees34K15K
StockData Score
Total score717 (better)
Valuation score05 (better)
Growth score22
Performance score45 (better)
Health score13 (better)
Dividend score02 (better)
Valuation
P/E71.0×13.7× (better)
P/S3.5× (better)3.6×
P/B6.4× (better)11.0×
EV/EBITDA19.5×10.5× (better)
P/FCF36.8×14.9× (better)
PEG–1.34
FCF yield2.7%6.7% (better)
Fair value$18.79$154.11
Margin of safety−127%45.8% (better)
Growth
Revenue growth (TTM)−15.2%1.5% (better)
Revenue growth, 5Y average0.71%7.2% (better)
Net income growth (TTM)–0.96%
EPS growth (TTM)–5.6%
EPS growth, 5Y average–12.0%
Profitability
Gross margin64.4%71.5% (better)
Operating margin11.4%–
Net margin5.0%27.5% (better)
FCF margin9.6%24.3% (better)
Return on equity9.7%64.4% (better)
Return on invested capital23.0%–
Financial health
Debt / equity0.58 (better)2.87
Net debt / EBITDA0.33 (better)1.85
Current ratio0.883.08 (better)
Altman Z-score0.874.07 (better)
Piotroski F-score88
Dividends and buybacks
Dividend yield–1.9%
Years of dividend growth–13
Dividend growth, 5Y average–19.0%
Buyback yield–10.6%
Shareholder yield0.00%12.5% (better)
Ownership
Held by institutions–96.1%
Held by insiders0.41%0.08%
Insider net buying, 12 months−$124M−$1.7M (better)
Superinvestors holding–3
Short interest, % of float2.4%4.1%

Go deeper

Other comparisons

For information only, not investment advice. Check the source filings before relying on any figure.